CAS Number146939-27-7
Synonyms5-{2-4-(1,2-benzothiazol-3-yl)piperazin-1-ylethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; ziprasidonum; Ziprasidone; UNII-6UKA5VEJ6X; 5-{2-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; ziprasidona; EINECS 203-794-9; 5-{2-[4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chlor-1,3-dihydro-2H-indol-2-on; Zipwell; MFCD00866661; 5-{2-[4-(1,2-Benzothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; ziprazidone; Ziprasidone [INN:BAN]; Geodon; Zeldox; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one
Molecular FormulaC21H21ClN4OS
Molecular Weight412.94 (anhydrous free base basis)
Purity≥97 (HPLC)%
Density1.4±0.1 g/cm3
Boiling Point554.8±50.0 °C at 760 mmHg
Melting Point213-215°C
Appearancepowder
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 146939-27-7 |
| Catalog No. | 2A-9059615 |
| Chinese Name | 齐拉西酮 |
| Synonyms | 5-{2-4-(1,2-benzothiazol-3-yl)piperazin-1-ylethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; ziprasidonum; Ziprasidone; UNII-6UKA5VEJ6X; 5-{2-[4-(1,2-Benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; ziprasidona; EINECS 203-794-9; 5-{2-[4-(1,2-Benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chlor-1,3-dihydro-2H-indol-2-on; Zipwell; MFCD00866661; 5-{2-[4-(1,2-Benzothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; ziprazidone; Ziprasidone [INN:BAN]; Geodon; Zeldox; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one |
| Molecular Formula | C21H21ClN4OS |
| Molecular Weight | 412.94 (anhydrous free base basis) |
| Purity | ≥97 (HPLC) |
| Density | 1.4±0.1 g/cm3 |
| Boiling Point | 554.8±50.0 °C at 760 mmHg |
| Melting Point | 213-215°C |
| Appearance | powder |
| Water Solubility | Water solubility: insoluble; water solubility: 2.1 |
| Storage Condition | Refrigerator |
| Packaging | II |
| Application | Ziprasidone (CP88059) is a 5-HT and dopamine receptor antagonist with antipsychotic activity. |
| HTC | 29211980 |
| SMILES | O=C1CC(C=C(C(Cl)=C2)CCN3CCN(CC3)C4=NSC5=C4C=CC=C5)=C2N1.[xHCl].[yH2O] |
| InChI | 1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27) |
| InChI Key | MVWVFYHBGMAFLY-UHFFFAOYSA-N |
| NACRES Code | NA.77 |
| UNSPSC | 12352200 |
| Hazard Symbols | 8 |
| MSDS | msds/59615_1_146939_27_7.pdf |
| Bioactivity | Ziprasidone(CP88059) is a combined 5-HT (serotonin) and dopamine receptor antagonist which exhibits potent effects of antipsychotic activity.IC50 value:Target: 5-HT receptor; Dopamine receptorZiprasidone possesses an in vitro 5-HT2A/dopamine D2 receptor affinity ratio higher than any clinically available antipsychotic agent. In vivo, ziprasidone antagonizes 5-HT2A receptor-induced head twitch with 6-fold higher potency than for blockade of d-amphetamine-induced hyperactivity, a measure of central dopamine D2 receptor antagonism. Ziprasidone also has high affinity for the 5-HT1A, 5-HT1D and 5-HT2C receptor subtypes, which may further enhance its therapeutic potential [1]. Ziprasidone sulfoxide and sulfone were the major metabolites in human serum. The affinities of the sulfoxide and sulfone metabolites for 5-HT2 and D2 receptors are low with respect to ziprasidone, and are thus unlikely to contribute to its antipsychotic effects [2]. Ziprasidone was associated with significant differential adverse effects relative to placebo in BPM, BPD, and schizophrenia with no significant difference in weight gain in all 3 groups. Self-reported somnolence was increased across the 3 conditions. Subjects with BPM were more vulnerable to EPS than those with BPD or schizophrenia [3].Clinical indications: Bipolar I disorder; Bipolar disorder; Mania; SchizophreniaFDA Approved Date: February 2001 Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease References [1]. Seeger, T.F., et al., Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther, 1995. 275(1): p. 101-13. [2]. Prakash, C., et al., Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos, 1997. 25(7): p. 863-72. [3]. Gao, K., et al., Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol, 2013. 33(3): p. 425-31. Chemical & Physical Properties Density 1.4±0.1 g/cm3 Boiling Point 554.8±50.0 °C at 760 mmHg Melting Point 213-215°C Molecular Formula C21H21ClN4OS Molecular Weight 412.94 Flash Point 289.3±30.1 °C PSA 76.71000 LogP 4.00 Vapour Pressure 0.0±1.5 mmHg at 25°C Index of Refraction 1.681 InChIKey MVWVFYHBGMAFLY-UHFFFAOYSA-N SMILES O=C1Cc2cc(CCN3CCN(c4nsc5ccccc45)CC3)c(Cl)cc2N1 Storage condition Refrigerator |
| Use of | Properties Articles28 Name ziprasidone Synonym More Synonyms Ziprasidone Biological Activity Related Catalog Signaling Pathways >> GPCR/G Protein >> 5-HT Receptor Signaling Pathways >> Neuronal Signaling >> 5-HT Receptor Signaling Pathways >> GPCR/G Protein >> Dopamine Receptor Signaling Pathways >> Neuronal Signaling >> Dopamine Receptor Research Areas >> Neurological Disease References [1]. Seeger, T.F., et al., Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther, 1995. 275(1): p. 101-13. [2]. Prakash, C., et al., Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos, 1997. 25(7): p. 863-72. [3]. Gao, K., et al., Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. J Clin Psychopharmacol, 2013. 33(3): p. 425-31. Chemical & Physical Properties PSA 76.71000 Index of Refraction 1.681 InChIKey MVWVFYHBGMAFLY-UHFFFAOYSA-N Storage condition Refrigerator |
| Transport Info | Shipping Name: UN |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Dangerous Regulations for land transport: 2252 International Dangerous Regulations for sea transport: 2252 International Dangerous Regulations for air transport: 2252 14.2 United Nations shipping name European Ground Transport Risk Regulation: 1,2-DIMETHOXYETHANE, solution IMDG Code: 1,2-DIMETHOXYETHANE, solution IFRS: 1,2-Dimethoxyethane, solution 14.3 Transport hazard categories European land transport Dangerous Regulations: 3 International sea transport Dangerous Regulations: 3 International air transport Dangerous Regulations: 3 14.4 Package group European Dangerous Regulations for land transport: II International Dangerous Regulations for sea transport: II International Dangerous Regulations for air transport: II 14.5 Environmental hazards European Land Transport Danger Regulations: No International Maritime Danger Regulations International Air Transport Danger Regulations: No Marine pollutants (yes/no): No 14.6 Special reminder to users No data available |
| Related Products in API & Advanced Intermediates | ||
|---|---|---|
| R(+)-Verapamil monohydrochloride hydrate | 38176-02-2 | 2A-9059547 |
| lenalidomide | 191732-72-6 | 2A-9059561 |
| Nortriptyline | 72-69-5 | 2A-9059585 |
| Trityl Valsartan | 783369-52-8 | 2A-9059598 |
| trityl olmesartan | 761404-85-7 | 2A-9059599 |
| Pemetrexed disodium | 15039-23-8 | 2A-9059634 |
| Codeine | 76-57-3 | 2A-9059636 |
| Erlotinib hydrochloride | 183319-69-9 | 2A-9059637 |
| Moxifloxacin | 151096-09-2 | 2A-9059655 |
| Acyclovir, Monophosphate | 66341-16-0 | 2A-9059678 |
| Browse all API & Advanced Intermediates products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS